Your browser is no longer supported. Please, upgrade your browser.
Eyenovia, Inc.
Index- P/E- EPS (ttm)-0.78 Insider Own18.50% Shs Outstand26.05M Perf Week6.25%
Market Cap102.18M Forward P/E- EPS next Y-0.96 Insider Trans7.81% Shs Float18.80M Perf Month-7.88%
Income-20.00M PEG- EPS next Q-0.23 Inst Own9.40% Short Float2.64% Perf Quarter-25.20%
Sales6.00M P/S17.03 EPS this Y36.30% Inst Trans2.23% Short Ratio1.11 Perf Half Y-21.76%
Book/sh0.16 P/B23.38 EPS next Y17.10% ROA-67.50% Target Price12.50 Perf Year8.41%
Cash/sh0.49 P/C7.57 EPS next 5Y- ROE-196.30% 52W Range3.39 - 7.72 Perf YTD-38.28%
Dividend- P/FCF- EPS past 5Y-16.90% ROI-125.20% 52W High-50.78% Beta1.99
Dividend %- Quick Ratio1.10 Sales past 5Y- Gross Margin60.00% 52W Low12.09% ATR0.30
Employees31 Current Ratio1.10 Sales Q/Q- Oper. Margin- RSI (14)43.02 Volatility5.43% 5.52%
OptionableYes Debt/Eq1.74 EPS Q/Q6.90% Profit Margin- Rel Volume0.69 Prev Close3.74
ShortableYes LT Debt/Eq0.00 EarningsNov 10 AMC Payout- Avg Volume448.08K Price3.80
Recom1.50 SMA20-0.16% SMA50-16.81% SMA200-24.27% Volume105,962 Change1.60%
Mar-01-21Initiated Northland Capital Outperform $10
Feb-03-20Downgrade Oppenheimer Outperform → Perform
Nov-17-21 12:00PM  
Nov-10-21 06:45PM  
Nov-08-21 08:00AM  
Nov-05-21 03:25PM  
Nov-04-21 04:05PM  
Nov-01-21 03:23PM  
Oct-29-21 05:28PM  
Oct-28-21 07:40AM  
Oct-26-21 11:00AM  
Oct-25-21 02:31PM  
Oct-05-21 08:21AM  
Oct-03-21 09:00AM  
Sep-30-21 06:38AM  
Aug-21-21 08:24AM  
Aug-19-21 07:28AM  
Aug-14-21 05:59AM  
Aug-11-21 04:05PM  
Jul-19-21 07:00AM  
Jul-07-21 04:01PM  
Jun-29-21 08:53AM  
Jun-15-21 08:00AM  
May-26-21 09:13AM  
May-25-21 11:18AM  
May-12-21 04:05PM  
May-10-21 08:30AM  
May-05-21 08:00AM  
Apr-21-21 01:57AM  
Apr-01-21 07:30AM  
Mar-25-21 04:05PM  
Mar-23-21 07:30AM  
Mar-18-21 08:00AM  
Mar-17-21 08:00AM  
Mar-10-21 08:00AM  
Mar-08-21 12:24AM  
Mar-02-21 07:30AM  
Feb-16-21 08:00AM  
Jan-26-21 07:30AM  
Jan-06-21 08:00AM  
Dec-29-20 07:00AM  
Dec-16-20 07:00AM  
Dec-08-20 01:23AM  
Dec-03-20 07:00AM  
Dec-02-20 07:07PM  
Nov-10-20 04:06PM  
Nov-09-20 03:30PM  
Nov-05-20 08:00AM  
Oct-13-20 03:40PM  
Oct-12-20 07:00AM  
Oct-05-20 07:00AM  
Sep-09-20 08:30AM  
Aug-26-20 07:31AM  
Aug-24-20 08:30AM  
Aug-21-20 04:05PM  
Aug-19-20 09:10AM  
Aug-18-20 04:03PM  
Aug-12-20 04:05PM  
Aug-11-20 08:00AM  
Jul-29-20 08:30AM  
Jul-20-20 03:30PM  
Jun-30-20 04:05PM  
Jun-11-20 04:10PM  
Jun-05-20 04:10PM  
May-13-20 04:05PM  
May-06-20 08:30AM  
Apr-22-20 10:10AM  
Mar-26-20 06:31AM  
Mar-25-20 04:05PM  
Mar-24-20 05:10PM  
Mar-23-20 06:35PM  
Mar-11-20 08:30AM  
Mar-04-20 08:30AM  
Feb-17-20 07:33AM  
Feb-10-20 09:25AM  
Dec-19-19 09:55AM  
Dec-02-19 09:02AM  
Nov-27-19 09:00AM  
Nov-13-19 04:05PM  
Nov-12-19 10:42AM  
Nov-11-19 11:24AM  
Nov-07-19 11:15AM  
Nov-06-19 09:56AM  
Eyenovia, Inc., a clinical stage ophthalmic company, engages in developing therapeutics based on its proprietary microdose array print (MAP) platform technology. The company focuses on to develop clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system. Its pipelines focus on the development of therapeutic indications for patients with progressive myopia and age-related near vision impairment or presbyopia indications; and microdose fixed combination ophthalmic pharmaceutical for mydriasis to address the eye exams with pupil dilation. The company's product candidates in pipeline include MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); and MydCombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; and a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine and MicroLine in China and South Korea. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Grant Stuart M.10% OwnerNov 16Buy3.5225,00088,0004,623,989Nov 17 07:00 AM
Grant Stuart M.10% OwnerNov 15Buy3.6475,000272,7504,598,989Nov 17 07:00 AM
Ianchulev TsontchoCHIEF EXECUTIVE OFFICERNov 03Buy4.0430,000121,206579,895Nov 03 07:54 PM
MATHER CHARLES E IVDirectorNov 01Buy3.834,00015,31430,359Nov 01 05:05 PM
Grant Stuart M.10% OwnerOct 29Buy3.7515,50558,1404,539,094Nov 02 06:57 AM
Rowe Michael MCHIEF OPERATING OFFICEROct 27Buy4.141,2004,9685,500Oct 27 04:02 PM
Grant Stuart M.10% OwnerOct 26Buy4.00100,000400,0004,523,589Oct 27 07:42 AM
Grant Stuart M.10% OwnerOct 25Buy4.0033,806135,2244,423,589Oct 27 07:42 AM
Rowe Michael MChief Operating OfficerSep 13Buy4.401,5006,6004,300Sep 13 05:04 PM
Grant Stuart M.10% OwnerAug 19Buy3.9850,000198,9844,389,783Aug 23 06:00 AM
Grant Stuart M.10% OwnerAug 18Buy3.939243,6354,339,783Aug 19 06:00 AM
Grant Stuart M.10% OwnerAug 17Buy4.0023,41993,6764,338,859Aug 19 06:00 AM
Clasby Jennifer GVP, Regulatory and ClinicalJun 17Option Exercise1.9524,51047,79480,212Jun 22 11:33 AM
LEE KENNETH B JRDirectorJun 15Buy5.412,00010,81225,359Jun 15 04:26 PM
LEE KENNETH B JRDirectorJun 14Buy5.472,00010,94023,359Jun 15 04:26 PM
LEE KENNETH B JRDirectorJun 11Buy5.382,00010,76021,359Jun 15 04:26 PM
MATHER CHARLES E IVDirectorMay 28Buy4.763,00014,26826,359May 28 04:09 PM
Rowe Michael MChief Operating OfficerMay 27Buy4.711,4006,5942,800May 28 01:38 PM
Grant Stuart M.10% OwnerApr 20Buy4.7830,000143,5004,315,440Apr 20 06:47 PM
Grant Stuart M.10% OwnerApr 19Buy4.8930,692150,1634,285,440Apr 20 06:47 PM
Grant Stuart M.10% OwnerMar 05Buy5.5035,000192,5004,254,748Mar 08 05:34 PM